The first cohort consisted of postmenopausal patients with early ER+ breast cancers (n = 79) who received adjuvant tamoxifen mono-therapy for 5 years (Supplementary Table 2) of which 68 had sufficient tumor tissue for MCM3 staining. This evidence concerns the gene ESR1 and breast cancer.